LIFECORE BIOMEDICAL, INC. Contract Liability (Deferred Revenue)
LIFECORE BIOMEDICAL, INC. (LFCR) had Contract Liability (Deferred Revenue) of $5.28 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $5.28M.
- 2026-03-31: Contract with Customer, Liability, Current $5.86M.
- 2025-12-31: Contract with Customer, Liability, Current $8.66M.
- 2025-09-30: Contract with Customer, Liability, Current $7.21M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.28M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $5.86M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $8.66M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $7.21M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.20M 10-Q · filed 2025-11-06 | |
| 2025-05-25 | $3.42M 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $2.56M 10-Q · filed 2025-04-03 | |
| 2024-05-26 | $2.11M 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $3.20M 10-Q · filed 2024-08-09 | |
| 2023-11-26 | $8.30M 10-Q · filed 2024-08-09 | |
| 2023-08-27 | $8.30M 10-Q · filed 2024-08-09 | |
| 2023-05-28 | $4.10M 10-Q · filed 2024-08-09 | $4.05M 10-K · filed 2024-03-20 |
| 2023-02-26 | $2.71M 10-K · filed 2024-03-20 | |
| 2022-11-27 | $731.00K 10-K · filed 2024-03-20 | |
| 2022-08-28 | $803.00K 10-K · filed 2024-03-20 | |
| 2022-05-29 | $919.00K 10-K · filed 2024-03-20 | |
| 2022-02-27 | $1.61M 10-K · filed 2024-03-20 | |
| 2021-11-28 | $967.00K 10-K · filed 2024-03-20 | $1.16M 10-Q · filed 2022-01-07 |
| 2021-08-29 | $1.07M 10-K · filed 2024-03-20 | $1.22M 10-Q · filed 2021-10-05 |
| 2021-05-30 | $287.00K 10-K · filed 2024-03-20 | $1.13M 10-K · filed 2021-07-29 |
| 2021-02-28 | $740.00K 10-K · filed 2024-03-20 | $1.59M 10-Q · filed 2021-04-08 |
| 2020-11-29 | $297.00K 10-K · filed 2024-03-20 | $644.00K 10-Q · filed 2021-01-07 |
| 2020-08-30 | $0.00 10-K · filed 2024-03-20 | $477.00K 10-Q · filed 2020-10-07 |
| 2020-05-31 | $352.00K 10-K · filed 2021-07-29 | |
| 2020-02-23 | $618.00K 10-Q · filed 2020-04-03 | |
| 2019-11-24 | $611.00K 10-Q · filed 2020-01-02 | |
| 2019-08-25 | $488.00K 10-Q · filed 2019-10-03 | |
| 2019-05-26 | $499.00K 10-K · filed 2020-08-14 | |
| 2019-02-24 | $1.29M 10-Q · filed 2019-04-04 | |
| 2018-11-25 | $1.72M 10-Q · filed 2019-01-07 | |
| 2018-05-27 | $2.63M 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |